Fifty 1 Labs to Host Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski
Fifty 1 Labs announces a virtual shareholder teleconference to discuss its strategic roadmap, including AI-driven drug repurposing and significant R&D investments, highlighting its commitment to innovation in health and wellness.
Fifty 1 Labs (OTC: FITY), a pioneer in AI-powered health and wellness solutions, has scheduled a virtual shareholder teleconference for July 28, 2025, at 12:00 PM EST. The event will be streamed live on X (formerly Twitter) and will feature Dr. James Orbinski, a Nobel Peace Prize laureate, discussing the company's strategic direction for its subsidiary, Fifty 1 AI Labs. Key topics include AI-driven drug repurposing for functional medicine, a $1 million R&D investment, and plans for a $5–10 million biotech acquisition by 2027.
The company's leadership has demonstrated their commitment to shareholder alignment through $350,000 in personal investments and deferred salaries until achieving a $50 million valuation or within a two-year timeframe. CEO Paul Arora emphasized the company's focus on off-patent drug repurposing and adaptive trials as pivotal for growth and making a global health impact. For more details, visit https://ibn.fm/xE7xs.